Public Company Healthcare

Vertex Pharmaceuticals

Boston, Massachusetts, United States

Vertex is a global biotechnology company investing in scientific innovation to create transformative medicines for people with serious diseases. Its work includes significant advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain, with a broad clinical pipeline across additional serious diseases.

Focus Areas
Biotechnology, Small-molecule therapeutics, Cell therapy
Website
www.vrtx.com

Tracked deals

3

3 tracked deals across 2022-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Vertex Pharmaceuticals Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Vertex Pharmaceuticals. 1 2022 ~2 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Vertex Pharmaceuticals Acquires Crinetics Pharmaceuticals
    September 1, 2026
    Buyer
    Vertex Pharmaceuticals Incorporated
    Target
    Crinetics Pharmaceuticals, Inc.
    Industry
    Pharmaceuticals
    Location
    California, United States
    Type
    Buyout

    Vertex Pharmaceuticals Incorporated completed its acquisition of Crinetics Pharmaceuticals, Inc. on September 1, 2026, in a transaction valued at approximately $10 billion in equity value. The acquisition adds PALSONIFY, atumelnant and other pipeline programs, establishing rare endocrine diseases as a new growth area for Vertex.

  • Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B
    July 5, 2026
    Buyer
    Vertex Pharmaceuticals
    Target
    Crinetics Pharmaceuticals, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for total equity value of about $10 billion ($8.8 billion net of estimated cash acquired). The deal—priced at $85 per share—was announced as a definitive agreement and is expected to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.

  • Vertex Pharmaceuticals Acquires ViaCyte for $320M
    July 11, 2022
    Buyer
    Vertex Pharmaceuticals
    Target
    ViaCyte
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions 2 tracked deals by Vertex Pharmaceuticals. Biotechnology Buyers & Acquisitions 1 tracked deal by Vertex Pharmaceuticals. Acquisitions in California 2 tracked deals by Vertex Pharmaceuticals.

Related articles

Selling a company? Get in front of buyers like Vertex Pharmaceuticals

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →